About Infervision
Infervision is a Healthcare company based in Beijing (China) founded in 2016 by Shaokang Wang and Kuan Chen. AI-based medical imaging solutions for clinical diagnosis are offered. Infervision has raised $212.96 million across 8 funding rounds from investors including GF Securities, European Union and Qiming Venture Partners. Its chief executive, as recorded, is Kuan Chen. Its focus areas include HealthTech, Healthcare IT, Provider and Clinical Operations. Its competitors include Airdoc and Hangzhou Jianhai Technology; 1 of its 2 listed competitors has raised funding.
Company details
Infervision was founded in 2016 and is headquartered in Beijing, China. Operations focus on the healthcare sector, where neural network technologies are developed for medical imaging analysis. Assistance is provided to physicians in diagnosing diseases and making treatment decisions through integrated platforms. Clinical workflows are supported for surgical planning and targeted interventions, enhancing precision in patient care.
- Headquarters Beijing, China
- Founders Shaokang Wang, Kuan Chen
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website infervision.com
- Social LinkedIn X Facebook
- Total Equity Funding$212.96M (USD)
in 8 rounds
- InvestorsGF Securities
& 18 more
Funding Insights of Infervision
Infervision has successfully raised a total of $212.96M across 8 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $212.96M
- Total Rounds 8
- First Round $1.6M
(Feb 2016)
- Investors Count 19
All 8 funding rounds of Infervision with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2021 | Series D | – | Goldman Sachs Asset Management | – | |
| Jul 2021 | $138.81M | Series D | – | ZPF Zhongguancun M&A Fund of Funds, CCB trust | |
| Apr 2020 | $327,980 | Grant | – | – | |
| Dec 2018 | Series C | – | CDH | ||
| Mar 2018 | $47.33M | Series C | – | – | |
| Sep 2017 | $18M | Series B | – | Qiming Venture Partners | |
| Jan 2017 | $7.21M | Series A | – | – | |
| Feb 2016 | $1.6M | Seed | – | – |
19 investors in total: 19 institutional.
Investors in Infervision
Infervision has secured backing from 19 investors, including institutional and venture fund investors. Prominent investors backing the company include GF Securities, European Union and Qiming Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| z-parkfund.com | ||||
Private equity and private debt firm focused on multiple sectors | cdhfund.com | Kowloon, China | ||
Early and growth-stage investments in China's TMT sector are targeted. | xianghecap.com | Haidian, China | ||
Venture capital investments are directed toward multiple sectors. | 2006 | qimingvc.com | Shanghai, China | |
| advantechcapital.com | ||||
Growth capital investments are managed by this private equity fund. | gcfunds.com | Beijing, China | ||
Sequoia Capital is engaged in venture capital investments. | 1972 | sequoiacap.com | ||
Early-stage venture capital investments are managed by the fund. | innoangel.com | Haidian, China | ||
| powercloudvc.com | ||||
Global asset management and investment solutions are provided. | 1989 | gsam.com | London, United Kingdom |
Investor details for Infervision
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Infervision
10 people are tracked at Infervision (9 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Shaokang Wang | Co-Founder | Leadership |
Kuan Chen | Founder & CEO | Leadership |
Bingshu Chen | Vice President of Goverment Affairs | Leadership |
Sergi Drago | EMEA Business Development Director | Leadership |
Annie DK | VP, Head of Global Public Affairs | Leadership |
Kuan Chen (CK 陈宽) | Founder | Leadership |
Yuan Cao | Vice President and BD Director | Leadership |
Karen Wang | Marketing VP | Leadership |
Stan Libo Tan | VP Product Marketing | Leadership |
Qingyue Zhang | Senior Product Marketing Manager | Team |
Complete people profiles for Infervision
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Infervision
3 dated milestones of Infervision across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Infervision is founded.
- Funding First funding round of $1.6M.
- Funding Latest funding round, Series D,.
Competitors of Infervision
Infervision has 2 listed competitors in our database, 1 of them funded. They include Airdoc and Hangzhou Jianhai Technology.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| airdoc.com | 2015 | Beijing, China | Offers decision support solutions | |||
| justhealth.cn | 2015 | Hangzhou, China | $131.26M | AI and cloud-based tools for healthcare disease management are developed. |
Detailed competitors of Infervision
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Infervision
The website of Infervision (infervision.com) receives about 2.4K visits a month.
- Monthly visits2.4K
▼ 32.9% vs previous month
Websites whose visitors overlap most with Infervision. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| baidu.com | 100% | 1.9B | #17 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Infervision
Complete news archive for Infervision
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Infervision
Infervision was founded in 2016.
Infervision is headquartered in Beijing, China.
Kuan Chen is the CEO of Infervision, as recorded in our data. They have also founded this company.
Infervision is a funded company, having raised a total of $212.96M across 8 funding rounds to date. The company's 1st funding round was a Seed of $1.6M, raised on Feb 2016.
Infervision was founded in 2016 and is headquartered in Beijing, China. Operations focus on the healthcare sector, where neural network technologies are developed for medical imaging analysis. Assistance is provided to physicians in diagnosing diseases and making treatment decisions through integrated platforms. Clinical workflows are supported for surgical planning and targeted interventions, enhancing precision in patient care.
Infervision's top competitors include Airdoc and Hangzhou Jianhai Technology.
Infervision has 19 investors. Key investors include GF Securities, European Union, Qiming Venture Partners, Haitong Securities, and Goldman Sachs Asset Management.